What's on the label is the measured result — net peptide mass, not gross powder weight, plus RP-HPLC purity, on a lot-numbered COA for every batch.
Net peptide mass and RP-HPLC purity — a lot-numbered COA for every batch.
Net peptide mass + HPLC purity, per lot.
PCAC will review 7 peptides for the 503A bulks list, BPC-157, KPV, TB-500, MOTS-c, Emideltide, Semax, Epitalon. Read our briefing →
PCAC will review 7 peptides for the 503A bulks list. Read →
FDA PCAC reviews 7 peptides in July. Read →
Growth-hormone-releasing peptide-6
PeptideXpo buyer fit
This PeptideXpo page is intentionally positioned for distributors, OEM buyers, and procurement teams comparing GHRP-6 inside a wider peptide catalog. It is not trying to be the deepest single-molecule monograph; the differentiated intent is assortment planning, export-ready documentation, fill-size comparison, and whether this SKU belongs in a broader buyer program.
Overview
GHRP-6 is a synthetic hexapeptide GHSR agonist within the GHRP family, distinguishable from its siblings (GHRP-2, Ipamorelin, Hexarelin) by its particular feature of producing robust appetite stimulation in addition to GH release. The appetite effect comes from GHRP-6's ghrelin-pathway activation at the hypothalamic-arcuate nucleus level, ghrelin is the endogenous appetite-stimulating hormone, and GHSR agonists at higher doses recapitulate part of ghrelin's appetite-driving activity. In research contexts, GHRP-6 is studied both for GH-release pharmacology and for orexigenic (appetite-stimulating) applications, making it the GHRP-family member most relevant to research workflows that want both effects rather than just one. PeptideXpo supplies GHRP-6 as a lyophilized powder at ≥99.0% HPLC purity. The hexapeptide is straightforward to synthesize and the analytical packet covers peak-integration HPLC plus mass spec. Two standard fill sizes (5 mg and 10 mg) cover typical research workflows. For research workflows specifically studying appetite-pharmacology, GHRP-6 is the most appropriate member of the GHRP family; for cleaner GH-selective work, Ipamorelin is preferred to avoid the appetite-and-cortisol confounders.
Who buys this, and why
GH-axis peptides ship to two main buyer types: compounding pharmacies dispensing under physician supervision, and research labs studying somatotropic-axis pharmacology. Pharmacies typically want sterile-filled vials with the full release packet (sterility, endotoxin, CCI); labs typically want bulk lyophilized powder with sequence verification. Blends (the CJC-1295 / Ipamorelin combination is the canonical example) are usually co-lyophilized rather than solution-mixed for potency stability.
Primary buyer fit: academic and contract research laboratories.
Specifications
Documentation available on request
Regulatory note
Sold as a bulk active for research and for compounding-pharmacy formulation where local regulations permit (notably 503A / 503B in the United States and analogous regimes elsewhere). Not a finished dosage form. Sterile-filled vials are available with full release documentation; the buyer is responsible for verifying scheduling and dispense requirements in the destination market.
Frequently asked questions
GHRP-6's defining feature among GHSR agonists is its substantial appetite-stimulating effect, at typical research doses, GHRP-6 produces measurable orexigenic activity that GHRP-2 (smaller appetite effect) and Ipamorelin (essentially no appetite effect) lack. The appetite stimulation comes from GHRP-6's binding profile at the hypothalamic-arcuate-nucleus GHSR, which is the same receptor that endogenous ghrelin engages to drive hunger signaling. The trade-off is a less GH-selective pharmacological profile compared to Ipamorelin. For research workflows specifically studying appetite pharmacology, GHRP-6 is the most appropriate GHRP-family choice; for clean GH-selective work, Ipamorelin remains the preferred tool.
Lyophilized GHRP-6 reconstitutes cleanly in bacteriostatic water for injection (BWFI) for multi-use research stocks or sterile water for injection (SWFI) for single-use preparations. The hexapeptide dissolves within 30-60 seconds with gentle swirl; do not vortex (the foaming entrains air and accelerates surface-mediated aggregation). The reconstituted solution should be aliquoted into single-use volumes immediately and held at -20 °C with strict freeze-thaw management, as with the rest of the GHRP family, freeze-thaw cycling is the dominant in-lab degradation pathway, not slow temperature drift. Working stocks are typically prepared at 1-5 mg/mL; for in vivo administration the working concentration is further diluted to the protocol-specified dose volume.
